BioSpace News Archive

Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska’s President & Chief Executive Officer, will present at the Raymond James 41st Annual Institutional Investors Conference on Tuesday, March 3, 2020 at 9:50 a.m. ET in Orlando, FL.

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, today announced financial results for the fourth quarter and full year ended December 31, 2019.

AppBus, an accelerator of business transformation, today announced it has partnered with Plecosystems (Pleco), a systems integration leader in the Life Sciences space.

IBM Watson Health (NYSE: IBM) today unveiled its newest cloud-based technology IBM Study Advance at the 11th Annual Summit for Clinical Ops Executives (SCOPE).

Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal trial.

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the initiation of the PATHFINDER Study.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that Cigna is now providing coverage for the Eversense® CGM System, effective February 15, 2020.

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will present at the Cowen and Company 40th Annual Healthcare Conference on Monday, March 2, 2020

Greenphire, the global leader in financial software for clinical trials, today announced that it has teamed with top industry sponsor, Roche (SIX: RO, ROG; OTCQX: RHHBY), to address the top hurdles patients face when participating in clinical trials.

Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatment of cancer and other diseases, today announced the appointment of Shattuck’s Chief Scientific Officer and Co-founder, Taylor Schreiber, M.D., Ph.D., to Chief Executive Officer.